Letrozole 2.5 - Saxon Pharmaceuticals

Introduced by Novartis in 1997 as Femara, letrozole quickly gained FDA approval for postmenopausal breast cancer. Its strength allows it to suppress estrogen production efficiently, even at low doses. As a non-steroidal aromatase inhibitor, it binds selectively, providing a powerful tool in managing estrogenic side effects. Side effects such as bone density reduction are noteworthy, highlighting the need for monitoring when used in non-medical settings like bodybuilding​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Letrozole 2.5 by Saxon Pharmaceuticals, consult with your doctor or healthcare professional.